Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo Aims to Enter Vaccine Market in Emerging Countries
August 16, 2010
- Shionogi: Crestor Pulls Up Sales 17.5%
August 16, 2010
- Medipal HD: Sales up 4.7% with Strong Increases in Profits
August 16, 2010
- 5 APIs, 7 Indications to Be Applied for Based on Data from Public Domain
August 16, 2010
- Taisho: Self-Medication Makes Up for Slump of Ethical Drugs
August 16, 2010
- Alfresa: Profits Up as a Result of Firm Pricing Policy
August 16, 2010
- Korosho Posts Its Policy for Assessment of Research Projects
August 16, 2010
- Ono: Sales Down 7.2% due to NHI Price Cuts, Competition with Generics
August 16, 2010
- Suzuken: Sales Up 1.7% Based on New Sales Reporting Method
August 16, 2010
- JAMS Proposes GLs for COI to Member Societies
August 16, 2010
- Santen: Tapros Drives Business
August 16, 2010
- Toho: Addition of Saywell, Asucome Boosts Sales
August 16, 2010
- 1st Japan-China Meeting of Health Authorities Held
August 16, 2010
- Kyorin: Sales Up 5.9% Driven by Strong Sales of Mainstay Products
August 16, 2010
- Negotiations Being Prolonged between Major Pharmacy Chains and Wholesalers
August 16, 2010
- Novartis Files DNA for COPD Treatment QAB149 in Japan
August 16, 2010
- Tsumura: Sales Up 1.9%
August 16, 2010
- Haruhiko Hirate to Oversee Takeda's Asian Operations
August 16, 2010
- Astellas to Apply for Degarelix for Prostate Cancer within 2010
August 16, 2010
- Kaken: Artz Drives Business
August 16, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…